ArticleClinical therapeutics2025
Oral Ursodeoxycholic Acid Is Associated With Decreased Rate of AMD.
Article in Clinical therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut-Brain Axis and Bile Acid Signaling: Linking Microbial Metabolism to Brain Function and Metabolic Regulation.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeCholelithiasis is associated with decreased risk of age-related macular degeneration (AMD). Ursodeoxycholic acid (UDCA), a bile acid used to dissolve cholesterol gallstones, has been shown to be retina-protective in several mouse models. This study sought to determine if UDCA may protect against AMD.
methodsA retrospective cohort study was conducted using data between January 1, 2000 to June 30, 2022 in Optum's de-identified Clinformatics Data Mart database. All patients had a history of cholelithiasis, cholecystitis, or cholecystectomy. The exposed cohort included patients taking UDCA. Controls did not take UDCA and were matched 1:3 for age (±3 years), sex, race, type of gallbladder disease, and insurance coverage start and end date (±4 months). All included patients were 55 years old or older, had at least two years of data in the dataset, and no prior history of AMD. Inverse probability of treatment weighting (IPTW) was used to balance covariates at baseline. Cox proportional hazard regression modeling with IPTW was used to compare progression to AMD between the cohorts.
findingsA total of 5,863 patients taking UDCA and 17,164 matched controls were analyzed. In both cohorts after IPTW, roughly 56% of patients had cholelithiasis, 16% had cholecystitis, and 28% had cholecystectomy. Age and sex were balanced at baseline between cohorts (UDCA: 70.5 ± 9.54 years old and 58.6% female; controls: 70.3 ± 9.59 years old and 57.4% female). In the UDCA cohort, 384/5,705 (6.74%) were diagnosed with AMD. In the control cohort, 1,559/17,322 (9.00%) were diagnosed with AMD. This corresponded to a significantly decreased hazard of AMD (adjusted hazard ratio = 0.65, 95% CI: 0.58-0.74, P < 0.0001). IMPLICATIONS: UDCA was associated with a 35% reduction in the hazard of AMD in patients with underlying gallbladder disease. Determining the mechanism for this protective effect could improve understanding of AMD pathogenesis. These results also suggest that clinical trials evaluating the use of UDCA for AMD could be valuable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.